Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T13:40:52.415Z.
Calculation as of: 2026-10-06T13:40:52.415Z.
Quote observation: 2026-10-06T13:30:03.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: b8bc85e2d5351a47333dd9131f39a7cf6b6d5f02586c5202dd123a5ad4370615
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Market Cap
$112.31M
Price/OCF Ratio
N/A
TTM Avg
8.98
3Y Avg
8.98
5Y Avg
8.98
Market Cap
$109.38M
Price/OCF Ratio
146.62
TTM Avg
45.05
3Y Avg
23.19
5Y Avg
15.20
Market Cap
$108.02M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$115.66M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Apyx Medical Corporation (APYX) | $110.75M | N/A | N/A | N/A | N/A |
| Immunic, Inc. (IMUX)vs › | $110.06M | N/A | N/A | N/A | N/A |
| Black Diamond Therapeutics, Inc. (BDTX)vs › | $112.31M | N/A | 8.98 | 8.98 | 8.98 |
| Cumberland Pharmaceuticals Inc. (CPIX)vs › | $109.38M | 146.62 | 45.05 | 23.19 | 15.20 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP)vs › | $108.02M | N/A | N/A | N/A | N/A |
| Lucid Diagnostics Inc. (LUCD)vs › | $113.55M | N/A | N/A | N/A | N/A |
| Coya Therapeutics, Inc. (COYA)vs › | $114.35M | N/A | N/A | N/A | N/A |
| LENZ Therapeutics, Inc. (LENZ)vs › | $114.76M | N/A | N/A | N/A | N/A |
| Aardvark Therapeutics, Inc. Common Stock (AARD)vs › | $115.66M | N/A | N/A | N/A | N/A |
| Foghorn Therapeutics Inc. (FHTX)vs › | $115.67M | N/A | 1.65 | 1.65 | 1.65 |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
